BioCentury | Jul 2, 2012
Clinical News

HI-1640V: Preliminary Phase IIb data

Preliminary data from the double-blind, Australian Phase IIb HI-H005 trial in 287 evaluable patients with moderate to severe COPD showed that oral HI-164OV did not reduce the number of exacerbations requiring corticosteroid treatment or hospitalization,...
BioCentury | Apr 2, 2012
Company News

Hunter Immunology, Probiomics deal

Probiomics completed its acquisition of Hunter Immunology after raising A$2.4 million ($2.5 million) in a public offer earlier in March. The company subsequently delisted from the Australian Securities Exchange (ASX) and implemented a 1-for-20 share...
BioCentury | Jan 2, 2012
Company News

Hunter Immunology, Probiomics deal

Hunter's board recommended that shareholders accept an October merger offer from probiotics company Probiomics. The stock deal values Hunter, an unlisted public company, at about A$29.7 million ($29.4 million). Details were not disclosed. Probiomics said...
BioCentury | Jul 18, 2011
Company News

Proquifin S.A. de C.V., Vanda sales and marketing update

...Vanda granted Proquifin's Probiomed S.A. de C.V. pharmaceutical operating unit exclusive rights in Mexico to commercialize schizophrenia...
...de C.V. pharmaceutical operating unit exclusive rights in Mexico to commercialize schizophrenia drug Fanapt iloperidone. Probiomed...
Items per page:
1 - 4 of 4
BioCentury | Jul 2, 2012
Clinical News

HI-1640V: Preliminary Phase IIb data

Preliminary data from the double-blind, Australian Phase IIb HI-H005 trial in 287 evaluable patients with moderate to severe COPD showed that oral HI-164OV did not reduce the number of exacerbations requiring corticosteroid treatment or hospitalization,...
BioCentury | Apr 2, 2012
Company News

Hunter Immunology, Probiomics deal

Probiomics completed its acquisition of Hunter Immunology after raising A$2.4 million ($2.5 million) in a public offer earlier in March. The company subsequently delisted from the Australian Securities Exchange (ASX) and implemented a 1-for-20 share...
BioCentury | Jan 2, 2012
Company News

Hunter Immunology, Probiomics deal

Hunter's board recommended that shareholders accept an October merger offer from probiotics company Probiomics. The stock deal values Hunter, an unlisted public company, at about A$29.7 million ($29.4 million). Details were not disclosed. Probiomics said...
BioCentury | Jul 18, 2011
Company News

Proquifin S.A. de C.V., Vanda sales and marketing update

...Vanda granted Proquifin's Probiomed S.A. de C.V. pharmaceutical operating unit exclusive rights in Mexico to commercialize schizophrenia...
...de C.V. pharmaceutical operating unit exclusive rights in Mexico to commercialize schizophrenia drug Fanapt iloperidone. Probiomed...
Items per page:
1 - 4 of 4